{
    "download_date": [
        "ClinicalTrials.gov processed this data on May 09, 2023"
    ],
    "link_text": [
        "Link to the current ClinicalTrials.gov record."
    ],
    "url": [
        "https://clinicaltrials.gov/show/NCT05481502"
    ],
    "org_study_id": [
        "2022-A00472-41"
    ],
    "secondary_id": [
        "2022/3404"
    ],
    "nct_id": [
        "NCT05481502"
    ],
    "brief_title": [
        "An Exploratory Study to Evaluate Immune Determinants of the Response to Adoptive Cell Therapy (ACT) in Solid and Hematologic Tumors"
    ],
    "acronym": [
        "PIONEER"
    ],
    "official_title": [
        "A Prospective Trial to Evaluate Immune Determinants of the Response and the Toxicity to Adoptive Cell Therapy (ACT) in Solid and Hematologic Tumors"
    ],
    "lead_sponsor": [],
    "source": [
        "Gustave Roussy, Cancer Campus, Grand Paris"
    ],
    "has_dmc": [
        "No"
    ],
    "is_fda_regulated_drug": [
        "No"
    ],
    "is_fda_regulated_device": [
        "No"
    ],
    "textblock": [
        "This is a study to explore the phenotypic and transcriptional changes of different cellular\r\n      components in the tumor following the injection of somatic cell therapy drugs.\r\n\r\n      The second objective is to explore phenotypic and transcriptional changes of different\r\n      cellular components in blood and bone marrow following injection of somatic cell therapy\r\n      drugs.Then correlate the phenotypic and transcriptional profile of different tumor, blood and\r\n      bone marrow immune populations with clinical response and/or toxicity. And to finish this\r\n      study is designed in order to identify a phenotypic, transcriptional and epigenetic profile\r\n      of intra-tumoral adoptive cells and correlate this profile with clinical response and/or\r\n      toxicity."
    ],
    "overall_status": [
        "Recruiting"
    ],
    "type": [
        "Actual",
        "Anticipated",
        "Anticipated",
        "Anticipated",
        "Actual",
        "Actual"
    ],
    "start_date": [
        "June 8, 2022"
    ],
    "completion_date": [
        "July 1, 2026"
    ],
    "primary_completion_date": [
        "July 1, 2026"
    ],
    "phase": [],
    "study_type": [
        "Interventional"
    ],
    "has_expanded_access": [
        "No"
    ],
    "allocation": [],
    "intervention_model": [
        "Single Group Assignment"
    ],
    "primary_purpose": [
        "Other"
    ],
    "masking": [
        "None (Open Label)"
    ],
    "measure": [
        "Comparison of frequency, phenotype and transcriptional profile of the different immune subsets in the tumor following adoptive cell therapy infusion using spectral flow cytometry and RNA sequencing",
        "Objective Response",
        "Progression-free survival",
        "Overall survival",
        "Safety of biopsies procedures (when applicable) graded according to CTCAE v5.0"
    ],
    "time_frame": [
        "3 months following ACT",
        "3 months following ACT",
        "5 years after first ACT infusion",
        "5 years after first ACT infusion",
        "From enrollment to 30 days after the last sample"
    ],
    "description": [
        "Defined by RECIST 1.1 score for lymphoma and solid tumors",
        "Defined as the time between the adoptive cell therapy and progression, or death whatever the cause, whichever occurs first.",
        "Defined as the time between the adoptive cell therapy injection and death whatever the cause",
        "3 biopsies will be collected: at baseline, at day+15 and optionally at relapse",
        "7 blood samples (25ml) will be taken: at day-7 before treatment start, at day0, at day+3, day+7, day+15, month+3 and at relapse",
        "If a bone marrow biopsy or aspiration is performed as part of routine care, 1 mL of bone marrow aspiration or one more biopsy will be sampled"
    ],
    "number_of_arms": [
        1.0
    ],
    "enrollment": [
        60.0
    ],
    "condition": [
        "Solid Tumor, Adult",
        "Solid Tumor, Childhood",
        "Hematologic Cancer"
    ],
    "arm_group_label": [
        "Patients receiving advanced therapy medicinal products",
        "Patients receiving advanced therapy medicinal products",
        "Patients receiving advanced therapy medicinal products",
        "Patients receiving advanced therapy medicinal products"
    ],
    "arm_group_type": [
        "Experimental"
    ],
    "intervention_type": [
        "Procedure",
        "Procedure",
        "Procedure"
    ],
    "intervention_name": [
        "Tumor biopsy",
        "Blood sample",
        "Bone marrow sample"
    ],
    "criteria": [],
    "gender": [
        "All"
    ],
    "minimum_age": [
        "2 Years"
    ],
    "maximum_age": [],
    "healthy_volunteers": [
        "No"
    ],
    "last_name": [
        "Camille BIGENWALD, Dr",
        "Cristina CASTILLA LLORENTE, Dr"
    ],
    "phone": [
        "+33(0)142114229",
        "+33(0)142114239"
    ],
    "email": [
        "camille.bigenwald@gustaveroussy.fr",
        "cristina.castilla-llorente@gustaveroussy.fr"
    ],
    "facility": [],
    "status": [
        "Recruiting"
    ],
    "contact": [],
    "contact_backup": [],
    "country": [
        "France"
    ],
    "verification_date": [
        "July 2022"
    ],
    "study_first_submitted": [
        "June 24, 2022"
    ],
    "study_first_submitted_qc": [
        "July 28, 2022"
    ],
    "study_first_posted": [
        "August 1, 2022"
    ],
    "last_update_submitted": [
        "July 28, 2022"
    ],
    "last_update_submitted_qc": [
        "July 28, 2022"
    ],
    "last_update_posted": [
        "August 1, 2022"
    ],
    "responsible_party_type": [
        "Sponsor"
    ],
    "mesh_term": [
        "Hematologic Neoplasms"
    ]
}